VerifyNow檢測是一種快速阿司匹林血液檢測方法，有助于鑒別服用阿司匹林，但是沒有完全獲得對心臟病發作和腦中風保護性作用的患者。這種檢測已經獲得了美國食品藥品管理局簽發的自動棄權許可，免除了該檢測只能夠在中等復雜實驗室進行操作的要求。

VerifyNow檢測方法是由Accumetrics公司(San Diego, CA, USA)研制開發的，是第一個獲得這種自動棄權許可的血小板功能試驗。這種檢查能夠很快得到一個簡單的數值，該結果能夠提示患者對阿司匹林有反應以及十分得到了充分保護，或者提示患者對阿司匹林沒有反應，從而患者患心血管疾病的危險增加。如果發現患者是無反應的，就需要增加劑量，調整同時使用的干擾阿司匹林效果的其它藥物，或者使用另外類型的抗血小板藥物。越來越多的證據顯示，多達30%每日使用阿司匹林期望獲得保護作用的患者對阿司匹林沒有足夠的反應。

美國普羅維登斯Saint Joseph醫院心血管醫生Mar Ladenheim說：“使用這種簡單的測試方法，患者能夠平靜地離開醫生診室，因為他們已經知道阿司匹林是否對他們起作用。或者他們是屬于那些沒有反應地患者，這就給了患者與醫生調整治療的機會，從而不會耽誤病情。”
 
Test for Aspirin Effectiveness
 
The VerifyNow aspirin test is a rapid blood test that helps to identify patients taking aspirin who are not receiving the full benefits of its protective effects against heart attack and stroke. The test has been granted a waiver by the U.S. Food and Drug Administration (FDA) eliminating the requirement that the test be performed only in moderately complex laboratories.

The VerifyNow test, developed by Accumetrics (San Diego, CA, USA), is the first platelet function assay to receive this waiver. The test provides a rapid result with one simple number indicating if a patient is responding to aspirin and adequately protected, or is unresponsive to aspirin and thus at increased risk for cardiovascular risks. If a patient is found to be nonresponsive, the dosage may need to be increased, the use of other drugs that can interfere with aspirin’s effect may need to be modified, or the use of another type of antiplatelet agent may be indicated. There is growing evidence that up to 30% of patients taking a daily aspirin for its protective effects do not fully respond to aspirin.

“With this one simple test, patients can leave the doctor’s office with the peace of mind of knowing that aspirin is working for them,” said Mar Ladenheim, M.D., a cardiologist at Providence Saint Joseph Hospital (Los Angeles, CA, USA). “Or if they’re among those who aren’t responding, this gives them the opportunity to work with their physician to modify treatment before it’s too late.”